Why the study?
Does apixaban effectively prevent and treat venous thromboembolism compared to traditional anticoagulants?
Does apixaban effectively prevent and treat venous thromboembolism compared to traditional anticoagulants?
This review summarizes the clinical utility of apixaban for VTE prevention and treatment, highlighting its noninferiority to traditional anticoagulants and providing guidance on perioperative management and bleeding complications.
May guide apixaban selection for VTE; leaves open needs for prospective validation in specific populations.
Anticoagulation with heparin and vitamin K antagonist has been the mainstay of prevention and treatment of venous thromboembolism (VTE) for many years. In recent years, novel oral anticoagulants such as dabigatran etexilate (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (a direct factor Xa inhibitor) have emerged for the prevention and treatment of VTE. Novel oral anticoagulants have been shown to be noninferior to vitamin K antagonist or heparin in the prevention and treatment of VTE. This review specifically examines the role of apixaban in the prevention and treatment of VTE based on the available literature. The management of apixaban in the perioperative setting is also explored because some patients on apixaban may require surgical intervention. Finally, we discuss the management of apixaban-induced major bleeding complications, the relevance of drug-drug interactions, and patient education.
No takes yet. Share an insight, caveat, or question.
Oo et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: